Get the Stockscreener App
2.70
0.37%
-0.010
After Hours:
2.70
Aytu Biopharma Inc stock is traded at $2.70, with a volume of 54,268.
It is down -0.37% in the last 24 hours and up +6.30% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
See More
Previous Close:
$2.71
Open:
$2.7
24h Volume:
54,268
Relative Volume:
0.60
Market Cap:
$27.51M
Revenue:
$66.38M
Net Income/Loss:
$-14.18M
P/E Ratio:
-0.9617
EPS:
-2.8074
Net Cash Flow:
$-5.17M
1W Performance:
+1.50%
1M Performance:
+6.30%
6M Performance:
+2.66%
1Y Performance:
+61.68%
1-Day Range:
$2.66
$2.75
1-Week Range:
$2.60
$2.85
52-Week Range:
$0.95
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.70 | 27.61M | 66.38M | -14.18M | -5.17M | -2.8074 |
|
ZTS
Zoetis Inc
|
124.05 | 54.82B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.29 | 50.36B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.46 | 46.00B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.81 | 36.32B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
468.94 | 20.33B | 3.08B | 1.24B | 1.07B | 25.61 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Aytu launches EXXUA, first selective 5-HT1A agonist for depression By Investing.com - Investing.com Canada
Aytu BioPharma Highlights EXXUA Opportunity at Investor Day - TipRanks
Aytu BioPharma Recaps Investor Day Held on January 20, 2026 - ACCESS Newswire
Aytu BioPharma Recaps Investor Day and EXXUA Launch - TradingView
New EXXUA depression drug targets MDD without sexual side effects - Stock Titan
AYTU: Exxua launches as a differentiated MDD therapy, targeting growth with disciplined, scalable execution - TradingView
AYTU: Exxua launches as a novel MDD therapy, targeting unmet needs with strong financial discipline - TradingView
Aytu launches EXXUA, first selective 5-HT1A agonist for depression - Investing.com
Aytu BioPharma (AYTU) Launches EXXUA for Treating Major Depressi - GuruFocus
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Di - PharmiWeb.com
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA - ACCESS Newswire
New depression drug EXXUA avoids sexual dysfunction and weight gain - Stock Titan
Will Aytu BioPharma Inc. (AY20) stock outperform global peersREITs Market Trends & Small Investment Big Gains - bollywoodhelpline.com
Aytu BioPharma Talks Exxua MDD Launch, Differentiation and RxConnect Access at Investor Summit - Defense World
AYTU: Exxua's launch leverages unique differentiation and RxConnect to target major growth in depression treatment - TradingView — Track All Markets
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 - ACCESS Newswire
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City - ACCESS Newswire
How Aytu BioPharma Inc. (AY20) stock reacts to fiscal policiesJuly 2025 Technicals & Stepwise Swing Trade Plans - ulpravda.ru
Buybacks Report: Is Aytu BioPharma Inc. stock dividend yield sustainableForecast Cut & Daily Volume Surge Signals - Улправда
Portfolio Recap: How sustainable is Aytu BioPharma Inc. stock dividend payoutQuarterly Market Summary & AI Enhanced Trading Alerts - Улправда
Why Aytu BioPharma Inc. stock attracts high net worth investorsMarket Risk Report & High Accuracy Trade Alerts - Улправда
Will Aytu BioPharma Inc. stock outperform tech sector in 2025July 2025 Sentiment & High Conviction Investment Ideas - Улправда
Why Aytu BioPharma Inc. stock is favored by top institutionsTreasury Yields & Comprehensive Market Scan Reports - ulpravda.ru
Entry Recap: Why Aytu BioPharma Inc. stock attracts high net worth investorsPortfolio Gains Summary & Weekly Top Stock Performers List - Улправда
Aytu BioPharma (AYTU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Published on: 2025-12-24 03:59:28 - moha.gov.vn
Can Aytu BioPharma Inc. stock sustain revenue growthJuly 2025 Outlook & Capital Efficiency Focused Strategies - Улправда
Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st
Is Aytu BioPharma Inc. stock attractive for income investors2025 Winners & Losers & Low Risk High Win Rate Picks - Улправда
Aytu BioPharma announces commercial availability of EXXUA tablets - MSN
Will Aytu BioPharma Inc. stock deliver shareholder valueTrade Performance Summary & Low Drawdown Trading Strategies - DonanımHaber
How sustainable is Aytu BioPharma Inc. stock dividend payoutEarnings Growth Summary & Safe Capital Allocation Plans - DonanımHaber
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City - ACCESS Newswire
Depression drug EXXUA takes center stage at New York investor event - Stock Titan
Aytu BioPharma launches depression drug EXXUA in U.S. market - Investing.com India
Aytu BioPharma launches depression drug EXXUA in U.S. market By Investing.com - Investing.com Nigeria
Aytu BioPharma stock rises after commercial launch of depression drug EXXUA - Investing.com Canada
Aytu BioPharma (AYTU) Launches EXXUA for Major Depressive Disorder in U.S. - GuruFocus
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults - Times Argus
Aytu BioPharma (Nasdaq: AYTU) makes EXXUA depression drug commercially available in US - Stock Titan
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome - ACCESS Newswire
AWM Investment Company Inc. Takes $1.35 Million Position in Aytu BioPharma Inc. $AYTU - Defense World
Aytu BioPharma (NASDAQ:AYTU) Given New $13.00 Price Target at Ascendiant Capital Markets - Defense World
Aytu BioScience Stockholders Approve Key Proposals - TipRanks
AYTU FinancialsIncome Statement - Quiver Quantitative
Ascendiant Capital Maintains Aytu BioPharma (AYTU) Buy Recommendation - Nasdaq
Ascendiant Capital raises Aytu Biosciences stock price target on Q1 beat - Investing.com Canada
AYTU Analyst Rating Update: Ascendiant Capital Raises Price Targ - GuruFocus
Revenue per share of Aytu BioPharma, Inc. – LSX:A3D38R - TradingView — Track All Markets
Will Aytu BioPharma Inc stock outperform Nasdaq index2025 Price Targets & Risk Controlled Daily Trade Plans - BỘ NỘI VỤ
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):